Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11694827rdf:typepubmed:Citationlld:pubmed
pubmed-article:11694827lifeskim:mentionsumls-concept:C0018939lld:lifeskim
pubmed-article:11694827lifeskim:mentionsumls-concept:C0032105lld:lifeskim
pubmed-article:11694827lifeskim:mentionsumls-concept:C0376705lld:lifeskim
pubmed-article:11694827lifeskim:mentionsumls-concept:C0332161lld:lifeskim
pubmed-article:11694827lifeskim:mentionsumls-concept:C0887947lld:lifeskim
pubmed-article:11694827lifeskim:mentionsumls-concept:C1707520lld:lifeskim
pubmed-article:11694827pubmed:issue3lld:pubmed
pubmed-article:11694827pubmed:dateCreated2001-11-5lld:pubmed
pubmed-article:11694827pubmed:abstractTextThe relationship between HIV-1 replication and hematologic parameters was examined in two separate studies. The first study was a cross-sectional evaluation of 207 untreated patients. In this study, the proportion of patients with hematologic disorders increased with disease progression. There was a significant inverse correlation between HIV-1 plasma viral load and all hematologic values (r = -0.266 to -0.331). The second study was a longitudinal evaluation of patients on combination antiretroviral therapy (HAART) with hematologic alterations before treatment ( N = 27 with platelets <150,000/microl, 24 with hemoglobin <12 g/dl, 36 with neutrophils <2000/microl and 29 with leukocytes <3000/microl). Samples were analyzed every 3 months for 2 years. At 2 years, >50% of patients experienced a sustained virologic response, with viral loads <500 RNA copies/ml. Hematologic reconstitution occurred progressively for all blood cell lineages and became statistically significant after the sixth month of therapy ( p <.001). Mean values increased from 110 to 180 x 10(3)/microl for platelets, from 10.7 to 12.3 g/dl for hemoglobin (stabilizing finally at 11.4 g/dl), from 1,260 to 2,240/microl for neutrophils, and from 2,260 to 3,600/microl for leukocytes. In conclusion, hematologic disorders are corrected by combination antiretroviral therapy. This suggests a causative role of HIV-1 in hematologic disorders.lld:pubmed
pubmed-article:11694827pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11694827pubmed:languageenglld:pubmed
pubmed-article:11694827pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11694827pubmed:citationSubsetIMlld:pubmed
pubmed-article:11694827pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11694827pubmed:statusMEDLINElld:pubmed
pubmed-article:11694827pubmed:monthNovlld:pubmed
pubmed-article:11694827pubmed:issn1525-4135lld:pubmed
pubmed-article:11694827pubmed:authorpubmed-author:SchneiderFFlld:pubmed
pubmed-article:11694827pubmed:authorpubmed-author:SchmitJ CJClld:pubmed
pubmed-article:11694827pubmed:authorpubmed-author:ServaisJJlld:pubmed
pubmed-article:11694827pubmed:authorpubmed-author:HemmerRRlld:pubmed
pubmed-article:11694827pubmed:authorpubmed-author:MoutschenMMlld:pubmed
pubmed-article:11694827pubmed:authorpubmed-author:RobertIIlld:pubmed
pubmed-article:11694827pubmed:authorpubmed-author:ArendtVVlld:pubmed
pubmed-article:11694827pubmed:authorpubmed-author:StaubTTlld:pubmed
pubmed-article:11694827pubmed:authorpubmed-author:NkogheDDlld:pubmed
pubmed-article:11694827pubmed:issnTypePrintlld:pubmed
pubmed-article:11694827pubmed:day1lld:pubmed
pubmed-article:11694827pubmed:volume28lld:pubmed
pubmed-article:11694827pubmed:ownerNLMlld:pubmed
pubmed-article:11694827pubmed:authorsCompleteYlld:pubmed
pubmed-article:11694827pubmed:pagination221-5lld:pubmed
pubmed-article:11694827pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:11694827pubmed:meshHeadingpubmed-meshheading:11694827...lld:pubmed
pubmed-article:11694827pubmed:meshHeadingpubmed-meshheading:11694827...lld:pubmed
pubmed-article:11694827pubmed:meshHeadingpubmed-meshheading:11694827...lld:pubmed
pubmed-article:11694827pubmed:meshHeadingpubmed-meshheading:11694827...lld:pubmed
pubmed-article:11694827pubmed:meshHeadingpubmed-meshheading:11694827...lld:pubmed
pubmed-article:11694827pubmed:meshHeadingpubmed-meshheading:11694827...lld:pubmed
pubmed-article:11694827pubmed:meshHeadingpubmed-meshheading:11694827...lld:pubmed
pubmed-article:11694827pubmed:meshHeadingpubmed-meshheading:11694827...lld:pubmed
pubmed-article:11694827pubmed:meshHeadingpubmed-meshheading:11694827...lld:pubmed
pubmed-article:11694827pubmed:meshHeadingpubmed-meshheading:11694827...lld:pubmed
pubmed-article:11694827pubmed:meshHeadingpubmed-meshheading:11694827...lld:pubmed
pubmed-article:11694827pubmed:meshHeadingpubmed-meshheading:11694827...lld:pubmed
pubmed-article:11694827pubmed:meshHeadingpubmed-meshheading:11694827...lld:pubmed
pubmed-article:11694827pubmed:year2001lld:pubmed
pubmed-article:11694827pubmed:articleTitleHIV-associated hematologic disorders are correlated with plasma viral load and improve under highly active antiretroviral therapy.lld:pubmed
pubmed-article:11694827pubmed:affiliationLaboratoire de Rétrovirologie, Centre de Recherche Public-Santé, Luxembourg.lld:pubmed
pubmed-article:11694827pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:11694827pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11694827lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11694827lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11694827lld:pubmed